Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Research Foundation v. Mylan Pharmaceuticals, No. 12-1523 (Fed. Cir. Aug. 7, 2013)

Affirmed in Part
Invalidity (§ 102/§ 103) Claim Construction Infringement
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 12-1523
Decided
August 7, 2013
Judge
Per curiam
Document
Nonprecedential Opinion
Length
9 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

In related district -court actions, plaintiff Galderma Laboratories, L.P., along with other patent -asserting parties, alleged that the Abbreviated New Drug Applica- tions submitted by Mylan Pharmaceuticals Inc., Lupin Limited, and Impax Laboratories, Inc. , each constituted an act of infringement under 35 U.S.C. § 271(e)(2).

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error